GE HealthCare Technologies Inc.

NasdaqGS:GEHC

Sector

🏥 Health Care

Industries

🩺 Medical Instruments

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

💻 Telehealth

Location

United States

Market Cap

USD 34.06 B

Share Price

USD 74.38

Avg Daily Volume

4,923,420

Change (1 day)

-0.64%

Change (1 year)

-5.63%

Change (YTD)

-4.86%

GE HealthCare Technologies Inc. Total Liabilities for the year ending December 31, 2024: USD 24.44 B

GE HealthCare Technologies Inc. Total Liabilities is USD 24.44 B for the year ending December 31, 2024, a -2.81% change year over year. Total liabilities are the total amount of a company's debts and other obligations.

GE HealthCare Technologies Inc. Total Liabilities for the year ending December 31, 2023 was USD 25.14 B, a 38.33% change year over year.
GE HealthCare Technologies Inc. Total Liabilities for the year ending December 31, 2022 was USD 18.18 B, a 88.71% change year over year.
GE HealthCare Technologies Inc. Total Liabilities for the year ending December 31, 2021 was USD 9.63 B, a 1.64% change year over year.
GE HealthCare Technologies Inc. Total Liabilities for the year ending December 31, 2020 was USD 9.48 B.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments	Receivables

NasdaqGS: GEHC

GE HealthCare Technologies Inc.

CEO	Mr. Peter J. Arduini
IPO Date	Dec. 15, 2022
Location	United States
Headquarters	500 West Monroe Street
Employees	53,000
Sector	🏥 Health Care
Industries Medical Instruments 🧬 Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals 💻 Telehealth

Description

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.